Clinical Trial

Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)

Name: Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2) — clinical trial record (NCT07299292)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Hypothesis The use of Abiraterone 250 mg with food + prednisone, without LHRH analogs or blockers (ADT), achieves castration-level testosterone at 30 days in ≥80-90% of cases.

Trial Details

NCT Number	NCT07299292
Lead Sponsor	SMED Clinical Research
Conditions	Prostate Cancer (Diagnosis)
Enrollment	60 participants
Start Date	2025-12-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-03-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-23